Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic heading into Phase III with Swiss partner Helsinn. Phase II data presented at the American Society of Hematology meeting in December 2016 suggested a complete response rate of 42% and median survival of 19.1 months for the drug in combination with Celgene's Vidaza (azacitadine) in older, treatment-naive AML patients, which compares well to historical controls. Gold discussed his company's plans for a large Phase III study with Helsinn and implications for interest in subtypes of the disease during an interview at Biotech Showcase.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: